| abstract |
Conjugates that bind VLA-4 are disclosed. Some of these conjugates also inhibit leukocyte adhesion, in particular leukocyte adhesion mediated by VLA-4. Such conjugates may be used in mammalian patients, such as humans, such as asthma, Alzheimer's disease, atherosclerosis, AIDS, dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis, and myocardial ischemia. Useful for the treatment of inflammatory diseases. The conjugate can also be administered to treat inflammatory brain diseases such as multiple sclerosis. |